CALL/AMGEN/200/0.1/17.01.25 | Real-time BOERSE MUENCHEN 08:25:30 2024-06-13 EDT | ||
| 9.7 EUR | -0.51% |
|
| Current month | -3.18% | ||
| 1 month | -8.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 9.7 | -0.51% |
| 24-06-12 | 9.75 | -1.22% |
| 24-06-11 | 9.87 | -1.30% |
| 24-06-10 | 10 | -2.34% |
| 24-06-07 | 10.24 | +1.79% |
Real-time BOERSE MUENCHEN
Last update June 13, 2024 at 08:25 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GZ9GC7 |
| ISIN | DE000GZ9GC75 |
| Date issued | 2023-03-01 |
| Strike | 200 $ |
| Maturity | 2025-01-17 (218 Days) |
| Parity | 10 : 1 |
| Emission price | 4.69 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.15 € |
|---|---|
| Lowest since issue | 3.162 € |
| Spread | 0.1 € |
| Spread % | 1.03% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
301.1
USD
Average target price
316.3
USD
Spread / Average Target
+5.05%
- Stock Market
- Warrants
- Warrant
